Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05274321 · ClinicalTrials.gov registry record · NA

Efficacy of the Nanodropper Device on Pupillary Dilation

A NA study, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
50
Enrollment target

NCT05274321: Completed NA study, sponsored by University of California, San Francisco.

NCT05274321 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05274321, a NA study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

Prescription eye drop bottles elute drops that exceed the capacity of the human eye by five times. This study describes performing in clinic dilation using a novel solution for combating medical waste with Nanodropper, an eye drop bottle adapter that creates smaller eye drops.

Primary Outcome

Cycloplegia is the paralysis of the ciliary muscle of the eye resulting in dilatation of the pupil and paralysis of accommodation. Cycloplegia is defined as the "change score." Change scores were calculated by subtracting the spherical equivalent value after dilation from the value before dilation for each eye.

Interventions

  • DEVICE Nanodropper
  • DEVICE Standard Eye Dropper

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-07-29
Est. Completion 2021-11-19
Phase NA

What the finished NCT05274321 record still lists

NCT05274321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Nanodropper is the first listed.

NCT05274321 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05274321 about?

NCT05274321 is a clinical study titled "Efficacy of the Nanodropper Device on Pupillary Dilation". Prescription eye drop bottles elute drops that exceed the capacity of the human eye by five times. This study describes performing in clinic dilation using a novel solution for combating medical waste with Nanodropper, an eye drop bottle adapter that creates smaller eye drops.

What is the current status of trial NCT05274321?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2021-07-29. Estimated completion is 2021-11-19.

What interventions are being tested in trial NCT05274321?

The interventions under investigation include: Nanodropper (DEVICE), Standard Eye Dropper (DEVICE).

Who is sponsoring clinical trial NCT05274321?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05274321's enrollment target sits among peer trials

50 1279th of 2000 higher than 622 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05274321, the US trial registry maintained by the National Library of Medicine. NCT05274321 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.